Drug Approval | March 10, 2026
FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
DiaMedica said it plans to launch the trial later in 2026
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Giri stated he is stepping down to pursue new opportunities after careful consideration
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Subscribe To Our Newsletter & Stay Updated
